ArticlePDF AvailableLiterature Review

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis

Authors:

Abstract

Calcineurin inhibitors (CNI) can suppress allo-and autoimmunity by suppressing T cell function but also have anti-proteinuric effects by stabilizing the cellular components of the kidney`s filtration barrier. Therefore, CNI are used in autoimmune kidney diseases with proteinuria. However, the traditional CNI, cyclosporine A and tacrolimus, have a narrow therapeutic range, need monitoring of drug levels, and their use is associated with nephrotoxicity and metabolic alterations. Voclosporin (VOC), a novel CNI, no longer requires drug level monitoring and seems to lack these adverse effects, although hypertension and drug-drug interactions still occur. VOC demonstrated efficacy superior to standard-of-care in controlling active lupus nephritis in the phase 2 AURA-LV and the phase 3 AURORA-1 trials and was approved for the treatment of active lupus nephritis. However, how to implement VOC into the current and changing treatment landscape of lupus nephritis is still debated. Here, we review the unique chemistry, pharmacology, and toxicity profile of VOC, summarize the efficacy and safety data from the AURA-LV and AURORA-1 trials, and discuss the following four possible options to implement VOC into the management of lupus nephritis, namely regarding B cell-targeting therapy with belimumab (BEL). These include: 1. patient stratification to either VOC or BEL, 2. VOC/BEL combination therapy, 3. VOC-BEL sequential therapy, or 4. alternative options for the rapid antiproteinuric effect of VOC.
Cells 2023, 12, 2440. https://doi.org/10.3390/cells12202440 www.mdpi.com/journal/cells
Review
Voclosporin: Unique Chemistry, Pharmacology and Toxicity
Profile, and Possible Options for Implementation into the
Management of Lupus Nephritis
Ajinath Kale 1, Vishwadeep Shelke 1, Yutian Lei 2, Anil Bhanudas Gaikwad 1 and Hans-Joachim Anders 3,*
1 Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333031,
India; ajinathk3@gmail.com (A.K.); vishwadeepshelke@gmail.com (V.S.);
anil.gaikwad@pilani.bits-pilani.ac.in (A.B.G.)
2 Division of Diabetology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians
University Munich, 333031 Munich, Germany; yutian.lei@med.uni-muenchen.de
3 Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians
University Munich, 80336 Munich, Germany
* Correspondence: hjanders@med.uni-muenchen.de; Tel.: +49-89-4400-32623
Abstract: Calcineurin inhibitors (CNI) can suppress allo- and autoimmunity by suppressing T cell
function but also have anti-proteinuric effects by stabilizing the cellular components of the kidney`s
filtration barrier. Therefore, CNI are used in autoimmune kidney diseases with proteinuria.
However, the traditional CNI, cyclosporine A and tacrolimus, have a narrow therapeutic range,
need monitoring of drug levels, and their use is associated with nephrotoxicity and metabolic
alterations. Voclosporin (VOC), a novel CNI, no longer requires drug level monitoring and seems
to lack these adverse effects, although hypertension and drug–drug interactions still occur. VOC
demonstrated efficacy superior to standard-of-care in controlling active lupus nephritis in the phase
2 AURA-LV and the phase 3 AURORA-1 trials and was approved for the treatment of active lupus
nephritis. However, how to implement VOC into the current and changing treatment landscape of
lupus nephritis is still debated. Here, we review the unique chemistry, pharmacology, and toxicity
profile of VOC, summarize the efficacy and safety data from the AURA-LV and AURORA-1 trials,
and discuss the following four possible options to implement VOC into the management of lupus
nephritis, namely regarding B cell-targeting therapy with belimumab (BEL). These include: 1.
patient stratification to either VOC or BEL, 2. VOC/BEL combination therapy, 3. VOC-BEL
sequential therapy, or 4. alternative options for the rapid antiproteinuric effect of VOC.
Keywords: calcineurin; autoimmunity; inflammation; proteinuria; podocytes; toxicity
1. Introduction
Calcineurin inhibitors (CNI) are a class of immunosuppressive drugs used to
suppress adaptive immunity during solid organ transplantation or in autoimmune
disease [1,2]. CNI are particularly aractive for the treatment of proteinuric kidney
diseases as unlike other immunosuppressants, CNI has specific antiproteinuric effects [3].
Indeed, autoimmune forms of glomerulonephritis can specifically benefit from this dual
mechanism of action but CNI are also used in podocytopathies of unknown causes [4].
However, nephrotoxicity limits the long-term use of CNI [5].
Cyclosporin A (CsA) was the first CNI in use but has a narrow therapeutic range and
a clinically relevant dose-dependent and dose-independent toxicity profile [6]. This
prompted the search for other CNI with beer toxicity profiles. Tacrolimus (TAC) was the
next CNI approved for the treatment of allo- and autoimmunity [7]. Tacrolimus still has a
narrow therapeutic range but comes with a partially different toxicity profile, which
Citation: Kale, A.; Shelke, V.; Lei, Y.;
Gaikwad, A.B.; Anders, H.-J.
Voclosporin: Unique Chemistry,
Pharmacology and Toxicity Profile,
and Possible Options for
Implementation into the
Management of Lupus Nephritis.
Cells 2023, 12, 2440. hps://doi.org/
10.3390/cells12202440
Academic Editor:
Duranton Christophe
Received: 14 September 2023
Revised: 9 October 2023
Accepted: 10 October 2023
Published: 11 October 2023
Copyright: © 2023 by the authors.
Licensee MDPI, Basel, Swierland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Aribution (CC BY) license
(hps://creativecommons.org/license
s/by/4.0/).
Cells 2023, 12, 2440 2 of 16
allows diversification of CNI’s use in patients with specific risk factors. However, CsA
and TAC both require monitoring of drug levels and are subject to numerous drug
interferences due to their specific mode of metabolism via cytochrome P450 [8]. VOC, a
more recently developed CNI, no longer requires monitoring of drug levels and has a
different toxicity profile [9]. Currently, VOC has only been tested in the clinical contexts
of kidney transplantation and lupus nephritis. Its potent antiproteinuric effect makes it a
perfect fit for this indication as the trial endpoint heavily relies on the proteinuria
response, which is more difficult to achieve for immunosuppressant agents that do not
directly modulate the glomerular filtration barrier. Here we review the molecular biology
of CN as a target treatment, the pharmacology and toxicity of available CNI, and the
potential use of VOC in the context of its latest approval for the treatment of active lupus
nephritis (LN) [10].
2. Calcineurin as a Molecular Drug Target
CN is a calmodulin/calcium-activated serine-threonine phosphatase that regulates
calcium signaling and immune and inflammatory processes. CN is a heterodimer
composed of two subunits: the catalytic A subunit and the regulatory B subunit [11].
Catalytic subunit A shares the major portion and is responsible for calmodulin binding
and associated downstream signaling. However, the regulatory subunit B has four
calcium binding sites sensitive to calcium signaling. The calcium and calmodulin-
mediated activation of calcineurin lead to the dephosphorylation of substrates involved
in several critical cellular processes (Figure 1). Those substrates are not limited to
receptors, channels, and proteins associated with microtubules and mitochondria, and,
more importantly, transcription factors [12]. The most commonly studied transcription
factors are nuclear factors of activated T-cells (NFAT 1-5), nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), the forkhead transcription factors, and
transcription factor EB. These factors drive the release of pro-inflammatory cytokines as
interleukins, interferons, CD40 ligand, tumor necrosis factors, and T-cell receptor (TCR)
signaling involved in the activation of T lymphocytes responding to foreign antigens,
autoantigens, or alloantigens [13]. Interleukins/cytokines further activate downstream
signaling via phosphatidyl-inositol-3 kinase, and the mammalian target of rapamycin,
which all regulate the activation, proliferation, and differentiation of T cells (Figure 1) [14].
Moreover, CN is also involved in the glomerular barrier function in kidney podocytes
(Figure 1). Podocytes are epithelial cells in the kidney glomeruli with an essential role in
maintaining integrity and function of the glomerular filtration filter [15]. Specifically, the
interdigitating podocyte foot processes, connected by proteins of the filtration slit in a
zipper-like structure to form a unique intercellular junction called a ’slit diaphragm’ that
is essential for the kidney filter [16]. Any focal or diffuse injury to podocytes and their foot
processes induces serum protein leakage into the urine, i.e., proteinuria [17]. Numerous
proteins are involved in connecting the actin cytoskeleton of podocytes with the proteins
in the slit diaphragm, e.g., synaptopodin [16]. Interestingly, CN can dephosphorylate
podocyte synaptopodin, which destabilizes the actin cytoskeleton, the podocyte
secondary foot processes, and the filtration slit [18]. Thus, CN-mediated
dephosphorylation of synaptopodin contributes to proteinuria, podocyte loss, and
glomerulosclerosis (Figure 1). Vice versa, CNI reverse these processes, and thus have
antiproteinuric and renoprotective effects [18–20]. Together, CN is a molecular target in
allo- and autoimmune and inflammatory diseases including SLE, LN, and other
proteinuric kidney diseases.
Cells 2023, 12, 2440 3 of 16
Figure 1. Roles of calcineurin in T lymphocytes (grey) and podocytes (pink). Phosphatase
calcineurin (CN) is a Ca++ sensitive enzyme in the nuclear factor of activated T cell (NF-AT)
signaling pathways downstream of the T cell receptor activated by foreign, auto-, or alloantigens.
Cyclosporin A (CsA), Tacrolimus (FK506) and Voclosporin (Voc) all block the phosphatase activity
of CN, albeit in different ways. In podocytes, CN dephosphorylates synaptopodin, a protein
involved in the stability of the actin cytoskeleton. CPN = cyclophilin; FK506 = tacrolimus; FKBP =
FK506-binding protein; CsA = cyclosporine A; Voc = voclosporin; IL = interleukin; TNF = tumor
necrosis factor; NF-AT = nuclear factor of activated T cells.
3. Chemistry of the Calcineurin Inhibitors
3.1. Cyclosporin
CsA is a cyclic undecapeptide (C62H111N11O12) with a molecular weight of 1202
Daltons, it is neutral, hydrophobic, and possesses eleven amino acid residues from which
seven amino acids are N-methylated, and the remainder are non-methylated [21,22].
During binding to cyclophilin, one N-methylated amino acid (Mle-3) bond of CsA remains
in the trans-orientation [23]. Due to N-methylated amino acids, there are fewer chances of
intramolecular hydrogen bonds, while the carbon chain of amino acid in position 1 (3-
hydroxy-4-methyl-2-methylamino-6-octanoic acid, abbreviated as MeBmt) is essential for
the bioactivity of CsA. The immunosuppressive effect significantly declines upon removal
of the non-polar part of the side chain [24]. Interestingly, the modifications at amino acid
2 with some alkyl chains, improve the immunosuppressive activity of CsA [23]. All 11
amino acids show an S-configuration of natural L-amino acids except for D-alanine in the
eighth position (R-configuration) and N-methyl-glycine in the third position. The
hydrolysis of CsA yields a cyclic derivative of MeBmt, while an acid treatment of CsA
provides iso-cyclosporine. X-ray crystallography and nuclear magnetic resonance
measurements confirm that CsA in crystal and soluble form mainly differ in their
respective confirmations due to the orientation of the carbon chain of the MeBmt amino
acid [25]. However, several analogs were generated to improve the potency and efficacy
of CsA.
Cells 2023, 12, 2440 4 of 16
3.2. Tacrolimus
TAC (also refered to as Fujimycin, tsukubaenolide, or FK506) is a member of the L-
pipecolic acid-derived macrolides class and has at least one deoxy sugar connected to a
large macrocyclic 14-16-membered ring as part of its 23-membered lactone ring [26]. The
molecular formula of TAC is C44H69NO12 with a molecular weight of 803.5 Daltons and is
generally found in a white to slightly off-white crystalline form. TAC is poorly soluble in
water and has a LogP value of 3.3. However, in aqueous solutions, TAC undergoes cis-
trans-isomerization and exists in three different forms, mainly due to changes at the C-12
position [27]. The limited and restricted rotation of the two amide bonds creates two
conformational rotamers of TAC. Importantly, tautomeric structural modifications can be
produced due to three adjacent carbonyl groups in the TAC ring, resulting in different
TAC analogs [28]. The pipecolic acid moiety, free hydroxy groups, and tricarbonyl groups
are essential for functional activity. The 2-propynyl group presented at the C-8 position is
important for the interaction with the FK-binding protein (FK-BP) and calcineurin
inhibition. Any modification at the C-8 position would result in instability in the FK-BP-
TAC complex [29]. Moreover, the 2-propynyl group at C-8 replaced with -CH2-CH3 or -
CH2-CH2=CH3 yields ascomycin and TAC 8-propyl analog, which further complicates
the purification of TAC [27].
3.3. Voclosporin or ISA247
VOC (C63H111N11O12) is a cyclic undecapeptide like CsA but with a molecular weight
of 1214.6 Daltons. It forms a heterodimeric complex with cyclophilin A that binds to CN
[30]. To create VOC, a single carbon extension was placed at the amino acid 1 position of
CsA. VOC is available in cis- and trans-isomers, from which the trans-isomer is considered
more potent. These two isomers differ in the orientation of one functional group [31,32].
Similar to CsA, modification at the amino acid 1 position with single carbon results in a
more prominent binding of the cyclophilin-VOC complex to the ‘latch-region’ of CN thus
increasing the potency of VOC [30]. More importantly, the amino acid 1 position is
essential for VOC metabolism. Therefore, any modifications at this position result in
shifting the metabolism site from the amino acid 1 to the amino acid 9 position, producing
less potent metabolite [33]. On the other hand, CsA undergoes a tremendous metabolism
and yields highly nephrotoxic metabolites, which limit the use of CsA in kidney disease
patients [34,35]. Therefore, the structural modifications at amino acid 1 renders VOC more
safe and more potent compared to CsA [35].
4. Pharmacology of the Calcineurin Inhibitors
4.1. Cyclosporine A (Sandimmune®, Neoral®)
Since 1980, CsA has been widely used in autoimmune and inflammatory disorders
and organ transplant recipients [36]. However, it has a narrow therapeutic range and can
cause serious side effects which limit its chronic use or its use as a first-line therapy in
many seings (Table 1) [36].
Table 1. The dosage, clinical indications, and adverse effects of calcineurin inhibitors.
Drugs Clinical Use Contraindications/
Adverse Effects
Cyclosporine
Solid organ transplantation (liver, kidney,
and heart), rheumatoid arthritis, psoriasis,
amyotrophic lateral sclerosis, nephrotic
syndrome, graft vs. host disease (GVHD),
refractory posterior uveitis, and Behcet
disease.
Contraindications: Amphotericin B, neomycin,
atorvastatin, cidofovir, elbasvir/grazoprevir,
flibanserin, lomitapide, mifepristone, tacrolimus,
life vaccines, etc.
Adverse effects: Dyslipidemia, hyperkalemia,
gynecomastia, hypertension, arrhythmia, decrease
Cells 2023, 12, 2440 5 of 16
Off-label: Allergic conjunctivitis, autoimmun
e
hepatitis, keratoconjunctivitis, Langerhans
cells histiocytosis, Duchenne muscular
dystrophy, ocular graft vs. host disease,
ulcerative colitis, pure red cell aplasia,
Henoch Schönlein purpura nephritis,
proteinuric forms of glomerulonephritis and
podocytopathies.
in eGFR and creatinine clearance, convulsions,
bleeding gums, GIT upset, infectious
complications.
Tacrolimus
Solid organ transplantation (liver, kidney,
and heart.
Off-label: Crohn’s disease, Graft-versus-host
disease (GVHD), Myasthenia gravis, and
Rheumatoid arthritis, Ulcerative colitis,
proteinuric forms of glomerulonephritis and
podocytopathies.
Contraindications: some antifungal agents,
polyoxyl 60 hydrogenated castor oil (HCO-
60), and
derivatives.
Adverse effects: Nephrotoxicity, neurotoxicity,
post-transplant diabetes mellitus, hypertension,
dyslipidemia, angina pectoris, cardiac arrhythmias,
urinary tract infections, cosmetic and electrolyte
disturbances, infectious complications.
Voclosporin
Active lupus nephritis.
Off-label: Plaque psoriasis, prevention of
organ rejection after transplantation, uveitis,
arthritis, and Crohn’s disease.
Contraindications: Phenylalanine, flunisolide,
bortezomib, cladribine, and in patients with renal
and hepatic impairments.
Adverse effects: Reduced eGFR, increased blood
pressure, diarrhea, headache, anemia, cough, UTI,
upper abdominal pain, dyspepsia, alopecia, renal
dysfunction, abdominal pain, mouth ulceration,
nausea, tremor, acute kidney injury and decreased
appetite, infectious complications.
Pharmacokinetic: CsA is available in liquid (oral or intravenous solution) and solid
dosage forms (capsules). Close therapeutic drug monitoring of CsA is recommended [37].
CsA is a lipophilic peptide and shows a variable pharmacokinetic profile. Oral absorption
of CsA is low which further decrease with the presence of food. Upon oral administration,
it can achieve bioavailability in a wide range [38]. CsA is extensively distributed in
peripheral tissues, blood erythrocytes, and plasma. It binds with albumin and lipoproteins
in the plasma [38]. The volume of the distribution of CsA lies between 3–5 L/kg and the
reported half-life varies from 5–27 h. The liver and intestines are the major sites wherein
CYP3A1,2,4,5,9, and CYP3C are the common enzymes responsible for CsA metabolism
[39]. AM1, AM1c, AM9, AM1c9, and AM4N are the CsA metabolites in which AM19 is the
major contributor to CsA-associated nephrotoxicity [6]. The underlying mechanisms of
CsA-induced nephrotoxicity are not entirely clear; however, the p38, JNK, ERK, and
MAPK subfamilies signaling are involved in CsA nephrotoxicity [40]. CsA is mainly
eliminated via biliary excretion and feces (~70%), and only 6–15% via the urine [41].
Contraindications: CsA shows significant interactions with certain medications such
as amphotericin B, neomycin, atorvastatin, cidofovir, elbasvir/grazoprevir, flibanserin,
lomitapide, mifepristone, tacrolimus, etc. The CYP3A4 inhibitors like macrolides,
verapamil, amiodarone, colchicine, oral contraceptives, and azole antifungals are known
to increase the plasma concentrations of CsA, TAC, and VOC when used concomitantly.
Moreover, CNI should not be given alongside CYP3A4 inducers which can decrease the
plasma concentrations of these drugs to subtherapeutic levels, e.g., carbamazepine,
orlistat, phenytoin, etc. Thus, close monitoring and/or dose adjustments are often required
when calcineurin inhibitors are used in combination with these drugs.
Adverse effects: Arterial hypertension, dyslipidemia, hirsutism, hyperuricemia,
hyperkalemia, and nephrotoxicity are more pronounced with CsA compared to TAC and
VOC (Table 2). CsA increases the low-density lipid, triglycerides, apolipoprotein B, and
Cells 2023, 12, 2440 6 of 16
lipoprotein (a) levels, and thus decreases the transportation of cholesterol to the intestines.
CsA also reduces the process of lipolysis and levels of high-density lipids. Other common
adverse effects include gynecomastia, arrhythmia, diabetes, a decrease in eGFR and
creatinine clearance, convulsions, bleeding gums, gingical hyperplasia, hypertrichosis,
and gastrointestinal upset.
Table 2. Comparison of major adverse effects of cyclosporine and tacrolimus with voclosporin.
Adverse Effects Cyclosporin Tacrolimus
Voclosporin
Hypertension ++ + +
Nephrotoxicity ++ ++ +
Decrease in eGFR + + +
Arrhythmia/cardiovascular risk + +
Anemia + + +
Neurotoxicity/convulsions + ++ +
Gastrointestinal upset + ++ +
Gum hyperplasia ++ +
Dyslipidemia ++ +
Gynecomastia +
Alopecia ++ +
Post-transplant diabetes mellitus + ++
Urinary tract infection + +
Hyperkalemia ++ + +
Cosmetic and electrolyte disturbances ++ +
Hyperuricemia ++ +
Hirsutism/hypertrichosis ++
++: more pronounced side effects, +: less pronounced side effects, −: no side effects.
4.2. Tacrolimus (Astagraf XL, Envarsus XR, Prograf, and Protopic)
TAC is a macrolide, one of the commonly prescribed immunosuppressants in
combination with other drugs to prevent solid organ transplant rejection (heart, liver,
lung, and kidney) [42]. Indeed, it is now used as a standard first-line therapy in kidney
transplant recipients. TAC is also approved to treat skin disorders such as atopic
dermatitis/eczema [43]. However, TAC has a narrow therapeutic window, its metabolism
is disturbed by various factors, and hence requires therapeutic drug monitoring [8,44]. It
also shows complex pharmacokinetics, pharmacodynamics, and pharmacogenetics
among organ transplant recipients which limits its clinical applications [45,46].
Pharmacokinetics: TAC is formulated in oral, intravenous, and topical dosage forms
(Table 1). The oral dosage form is designed in different release paerns: immediate, slow,
and extended release [47]. It combines with one or more therapies such as monoclonal
antibody-basiliximab, or drugs, such as sirolimus, azathioprine, mycophenolate mofetil,
and steroids [48–50]. TAC is metabolized by CYP3A4, CYP3A5, and P-glycoprotein
(PGP)/ABCB1 into the different metabolites, among which the main and major metabolite
is 13-O-dimethyl-tacrolimus [45]. The half-life ranges from 4 to 41 h, and the approximate
volume of distribution is 30 L/kg [45]. It is mainly excreted by the biliary route (~95%) and
2–3% is unchanged in the urine.
Contraindications: Antifungal agents and multiple other drugs metabolized by
CYP450 enzymes, including polyoxyl 60 hydrogenated castor oil (HCO-60), and their
derivatives require close drug level monitoring and/or dose adjustment to avoid TAC
toxicity [51].
Adverse effects: Post-transplant diabetes mellitus, neurotoxicity, GIT upset, and
alopecia are more pronounced with TAC when compared to CsA and/or VOC (Table 2).
It causes diabetes by stimulating glucolipotoxicity in β cells and thus leads to decreasing
Cells 2023, 12, 2440 7 of 16
insulin secretion. Nephrotoxicity, hypertension, dyslipidemia, angina pectoris, cardiac
arrhythmias, hyperkalemia, urinary tract infections, cosmetic, and electrolyte
disturbances are other common adverse events associated with TAC [52].
4.3. Voclosporin (Lupkynis™)
Voclosporin is a potent cyclosporine derivative, safer, more efficacious, and tolerable
than other calcineurin inhibitors [53]. VOC received clinical approval from the USFDA to
be used in combination with MMF and corticosteroids for treating LN [10]. However,
against psoriasis, it is inferior to CsA in terms of efficacy.
Pharmacokinetics: VOC is available only in oral solid dosage form. For treating LN,
the starting dose of VOC is 23.7 mg twice a day, with 8 or 12 h intervals (Table 1) [10].
VOC is recommended to be consumed on an empty stomach for its maximum absorption
and optimum bioavailability. The Tmax lies between 1 and 4 h and Cmax is estimated at
955.5 ng/mL
(hps://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf,
Accessed on 10 January 2023). Moreover, 2154 L/kg is the apparent volume of distribution
of VOC. Orally administered VOC is extensively metabolized by CYP 450 (3A4/5) in the
liver, hence drugs with CYP450 induction or inhibition properties are not recommended
to be administered concomitantly
(hps://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf,
Accessed on 10 January 2023). The half-life of VOC ranges from 25 to 36 h, the mean
apparent steady-state clearance is 63.6 L/h, and it is excreted in feces (~88%) and urine
(~2%) [10,31]. It is advised to be used in patients with a baseline eGFR of >45 mL/min/1.73
m2 wherein continuous eGFR monitoring is required. Moreover, it should be avoided in
patients with eGFR of ≤45 mL/min/1.73 m2 or a baseline blood pressure of >165/105 mmHg
and mild-to-moderate hepatic impairment.
Compared to other CNI, VOC has linear and predictable pharmacokinetic profiles
[54]. Unlike CsA and TAC, it does not require therapeutic drug monitoring and thus a
fixed dose can be prescribed. In addition, when CsA and MMF are combined, the
enterohepatic circulation of MMF is inhibited, and plasma concentrations of
mycophenolic acid (MPA) will be lower. Voclosporin does not affect the enterohepatic
circulation of MMF, leading to higher MPA exposure and potentially beer efficacy
compared to an equivalent MMF dose combined with CsA [55]. In kidney transplant
recipients and plaque psoriasis patients, VOC showed a strong correlation between dose,
its systemic concentration, CN inhibition, efficacy, and the threat of adverse events [56,57].
Contraindications: CYP3A4 induces or inhibits P-gp and OATP1B1 substrates
(statins), phenylalanine, flunisolide, bortezomib, and cladribine in patients with renal and
hepatic impairments. Close monitoring as well as dosage adjustment are recommended
when VOC is used along with such drugs.
Adverse effects: Overall, the safety profile of VOC is good when compared to CsA
and TAC (Table 2). VOC has not been reported to produce the other CNI related serious
adverse effects such as diabetes, gum hyperplasia, dyslipidemia, arrhythmia, and
disturbance in electrolyte balance and metabolic profile. Other common but non-serious
adverse effects, including increased blood pressure, diarrhea, headaches, anemia, coughs,
UTIs, upper abdominal pain, dyspepsia, alopecia, abdominal pain, mouth ulceration,
nausea, tremors, and decreased appetite, were occasionally observed. The most common
adverse effect from VOC was a transient drop in eGFR.
5. Experience with Calcineurin Inhibitors in Autoimmune Glomerulonephritis
and Podocytopathies
The current KDIGO guidelines recommend the use of CNI as a second line treatment
in a number of autoimmune glomerular diseases, namely for beer control of proteinuria
[58]. Especially in podocytopathies presenting as steroid-dependent nephrotic syndrome,
CNI are used as steroid-sparing agents [17,58]. In cases of steroid-resistant nephrotic
Cells 2023, 12, 2440 8 of 16
syndrome, CNI are in use while awaiting the results of genetic testing [4]. In membranous
nephropathy, a glomerulonephritis with an autoimmune podocyte injury [59,60], the
results of the MENTOR trial have reduced the enthusiasm for the use of CsA because B
cell depletion with rituximab was equally effective but, unlike CsA, did not show
nephrotoxicity [61]. TAC in combination with rituximab was beer tolerated but was
inferior to cyclophosphamide in this context [62]. In contrast, studies from China
convincingly demonstrate the superiority of a combination of MMF and TAC to reach
traditional trial endpoints in LN that heavily depend on the proteinuria response [63,64].
Confirmation from other world regions remained pending due to the lack of sponsor
interest to invest into trials with “old” drugs. This changed with the introduction of VOC.
5.1. Preclinical Data of Voclosporin and the Rationale to Develop Voclosporin for
Lupus Nephritis
VOC can aenuate the severity of disease in rodent models of autoimmune uveitis
and corneal inflammation [65,66]. However, experimental data on animal models of
autoimmune glomerulonephritis, LN, or other proteinuric kidney diseases, have not been
reported in the public domain. There may be reasons for this lack of preclinical data. The
mechanism of action of CNI is well established. Mouse models of SLE respond to the
traditional CNI, especially in terms of proteinuria control [67,68]. In addition, mice are not
a sensitive tool for a subtle drug safety analysis. In the clinical seing, most LN trials
testing modulators of adaptive immunity failed to reach the primary endpoint that
heavily relies on proteinuria control [69]. Indeed, an anti-proteinuric drug may be more
likely to reach standard endpoints in LN trials, with or without a capacity to suppress
autoimmunity, than a potent immune modulator because the processes underlying
proteinuria only indirectly relate to the immune system [70]. Hence, immunotherapies
acting outside of the kidney can control proteinuria only with some delay, while
antiproteinuric drugs, including CNI, show a more rapid response [59]. Finally, the
market potential of LN may exceed that of other autoimmune and proteinuric kidney
diseases [3].
5.2. Clinical Efficacy Data of Voclosporin in Lupus Nephritis
Clinical efficacy of VOC in LN was tested in the phase 2 AURA-LV and the phase 3
AURORA-1 studies in 265 patients requiring treatment for a first diagnosis or relapse of
biopsy-proven LN [53,71]. The AURA-LV study tested two oral doses of 23.7 mg VOC or
39.5 mg VOC or a placebo as an add-on to 2g/d mycophenolate mofetil (2 g/d), and rapidly
tapered oral corticosteroids [71]. A total of 32.6% of the low-dose VOC group achieved a
complete renal response at week 24, 27.3% of the high-dose VOC group, and 19.3% of the
placebo group. The significantly greater CRR rate in the low-dose VOC group persisted
for up to 48 weeks [71].
The AURORA-1 trial included SLE patients who had a kidney biopsy within 2 years
showing proliferative LN class III or IV, membranous LN class V, or combinations of these
[53]. Patients received either oral 23.7 mg VOC twice daily or a placebo as add-on to a
background of mycophenolate mofetil (2 g/d) and rapidly tapered oral corticosteroids.
The primary endpoint of a complete renal response at 52 weeks was defined as a
composite of proteinuria of 0.5 or less, stable estimated glomerular filtration rate (eGFR)
≥60 mL/min/1.73 m2, or no GFR decline from baseline of >20%, no rescue medication, and
no more than 10 mg prednisone equivalent per day [53]. The 357 patients were
randomized in a 1:1 ratio. A total of 41% of VOC-treated patients reached a complete renal
response at week 52 compared to 23% of the placebo group with an odds ratio of 2.65; 95%
CI 1.64–4.27; p < 0.0001). The majority of patients reached proteinuria treatment targets as
defined by the current EULAR/ERA recommendations [69,72]. These are similar to what
has been proposed for lupus nephritis by the global KDIGO guidelines [73]. It is of note
that a difference in proteinuria control between the two groups was evident as early as
two weeks after the start of VOC, which is unique among the non-CNI drugs used in the
Cells 2023, 12, 2440 9 of 16
LN sphere. Meanwhile 2 year follow-up analyses have been reported that document a
persistent benefit of VOC-treated patients in terms of this endpoint [74]. It is of note that
the parameters of systemic autoimmunity and extrarenal manifestations of SLE were
hardly assessed in this trial [53]. Complement and anti-dsDNA levels were not much
different between the groups further supporting the predominant antiproteinuric effect of
VOC [53]. Thus, the two trials confirmed that the antiproteinuric effect of CNI in
combination with MMF is potent enough to meet traditional trial endpoints in LN in
patients from various world regions, validating earlier Chinese studies. Thus, VOC shares
the immunosuppressive and antiproteinuric effects with the traditional CNI.
5.3. Clinical Safety Data of Voclosporin in Lupus Nephritis
Even novel immune modulators are still associated with adverse events, namely
infectious complications [75]. The safety analysis of the AURA-LV trial revealed more
serious adverse events in both VOC groups, and more deaths in the low-dose group
compared to the placebo and high-dose VOC groups (11.2%, 1.1%, and 2.3%, respectively)
[71]. Although these results raised some concerns, the safety analysis of the AURORA-1
trial displayed different results. Pneumonia occurred in 4% of VOC and 4% of placebo-
treated patients [53]. Six patients died during the study and follow-up period, of which
only one was treated with VOC. None of the fatal events were considered related to the
study treatments. Similarly, in the AURORA 2 follow-up study, a total of 216 patients
continued from the AURORA 1 trial, among which 116 were VOC treated while the rest
were in the control group; the investigators found that the treatment with VOC did not
increase chronic injury and helped in minimizing the renal histological changes [76].
These two follow-up data from different studies suggest that VOC is safer, and other side
effects matched the known safety profile of CNI, such as occasional hypertension or a
transient drop in GFR [53]. However, as judged by the estimated GFR, nephrotoxicity was
not observed during the reported two years of follow up. GFR remained stable in both
treatment groups [74]. Other adverse effects known from CsA or TAC such as gingival
hyperplasia, diabetes or hyperlipidemia were not observed [53]. Thus, VOC seems to have
a beer safety profile than other CNI, especially regarding metabolic disturbances and
long-term nephrotoxicity.
5.4. How to Integrate Voclosporin into the Treatment Landscape of Lupus Nephritis
Based on the results of the AURORA-1 trial, numerous countries approved VOC for
the initial treatment of active LN [10]. This approval is very welcome in the community
but raises numerous questions about how to implement VOC into the current treatment
landscape. Meanwhile, Belimumab (BEL) had also been approved for the same indication
based on the results of the BLISS-LN trial [77]. In contrast to VOC, BEL is well known to
rheumatologists as BEL has been in use for the treatment on non-renal SLE since 2011 and
has demonstrated good long-term efficacy on SLE activity and non-renal SLE
manifestations at a comfortable safety profile [78]. As such data are lacking for VOC, the
predominant advantage of VOC over BEL seems to be its capacity to control proteinuria
much faster than BEL [53,77]. Rapid control of proteinuria might help to avoid irreversible
kidney injury early in the disease course [79], but data supporting this concept are still
pending. Indeed, the AURORA-1 trial included a subset of patients that underwent repeat
biopsy, which would allow us to see if VOC-treated patients develop less chronic lesions.
However, for the moment, a specific renoprotective effect of early proteinuria control
remains speculative. Various concepts of how to implement VOC in the management of
LN are possible (Figure 2).
5.4.1. Option 1—Patient Selection
Rovin et al. started out with a pragmatic proposal to consider BEL and VOC as
second line drug options only for those patients not adequately responding to standard-
Cells 2023, 12, 2440 10 of 16
of-care within the first 3 months of treatment [80]. They proposed a threshold of 25%
reduction in proteinuria as a marker of non-response [80] but without specifying whether
this includes low-salt diet, a maximal tolerated dose of renin-angiotensin-system (RAS)
inhibitors, and an inhibitor of sodium-glucose transporter-2 (SGLT2) or not, which all
have substantial impact on proteinuria levels independent from the immunological SLE
activity [70]. The choice for either BEL or VOC would consider an individual cost–benefit
assessment as performed elsewhere [81]. Rovin et al. proposed a preference of BEL over
VOC in patients on MMF with a residual proteinuria of <3 g/d [80]. This option
acknowledges that a significant number of patients can reach a treatment response
without any of the new drugs and that limited resource seings may not be able to afford
the new drugs in all patients. However, as a limitation, a partial proteinuria response as a
guidance factor is subject to numerous confounders of proteinuria as a criterion for
treatment decisions in LN. For example, being overweight, having a salty diet, non-use of
RAS inhibition, and the use of dihydropyridin therapy to control hypertension may
explain an insufficient drop in proteinuria not necessarily requiring BEL or VOC add-on
therapy but other interventions.
5.4.2. Option 2—Combination Therapy
BEL and VOC both improve responder rates, but still a significant number of patients
do not reach a complete renal response [53,77]. Thus, combining the B cell deactivator BEL
and the T cell suppressor and podocyte protector VOC may have synergistic effects in
controlling all aspects of LN. As of now, this concept has not been tested in a controlled
study and not even case reports or series have been reported. Therefore, caution is
warranted regarding possible drug interferences and toxicity profiles. However, as
belimumab is not metabolized in the liver, the risk for interferences may be limited to a
possible additive effect on host defense and infectious complications. Given the different
sponsors of BEL and VOC, such a trial is unlikely to be conducted. As another limitation,
costs for such a treatment regime would hardly be affordable in most regions of the world.
Cells 2023, 12, 2440 11 of 16
Figure 2. Four different options for the implementation of voclosporin into the treatment landscape
of lupus nephritis. The different colors of grey indicate relative dosage. MMF = mycophenolate
mofetil, MPA = mycophenolic acid, VOC = voclosporin, BEL = belimumab, RASi = renin-angiotensin
system inhibitor, SGLT2i = sodium-glucose transporter-2 inhibitor.
5.4.3. Option 3—Sequential Therapy
The strength of VOC is rapid proteinuria control [53], which qualifies VOC for
immediate use in the management of LN in cases where rapid proteinuria control would
be associated with long-term benefits, e.g., by avoiding irreversible injury in this phase.
By contrast, the mechanism of action of BEL is rather long-term by controlling the
autoreactive lymphocytes clones that drive SLE activity and trigger flares of LN [82]. In
this regard, one could imagine the sequential use of VOC and BEL or starting LN therapy
with both of them and stopping VOC after 6 months when the effect of BEL kicks in.
Cells 2023, 12, 2440 12 of 16
However, such a regimen would be costly and data to support a sequential therapy
regimen are lacking so far.
5.4.4. Option 4—Other Antiproteinuric Drugs
In health care seings with limited availability or reimbursement of VOC, CsA and
TAC may appear as more affordable alternatives given they have the same mechanism of
action [3]. However, the main advantages of VOC over these drugs are that it lacks the
need for drug level monitoring and the much beer safety profile. Nephrotoxicity
especially limits the use of CsA on the long-term [5], as recently confirmed in the
MENTOR trial where CsA was tested against Rituximab in primary membranous
nephropathy [61]. Other antiproteinuric drugs that might replace VOC in this regard in
the early phase of disease exist, e.g., RAS inhibitors or SGLT2 inhibitors, which reduce
proteinuria by modulating glomerular hemodynamics and filtration pressure [83]. Such
drugs lack any immunosuppressive effects, but it is currently unclear to what extent the
long-term results of the AURORA-1 trial relate to the immunosuppressive effects of VOC
or to their antiproteinuric effects at the filtration barrier [53]. However, in this case, VOC
would be preferentially given in a sequential therapy approach, these drugs may to some
extent substitute for the rapid antiproteinuric effect of VOC and even contribute to a
renoprotective effect by antagonizing the non-immune mechanisms of LN progression
[84,85]. This might be a possibility in seings with limited resources for costly drugs.
However, RAS/SGLT2 blockades may make more sense, when used in combination with
BEL to suppress SLE activity and LN relapses by targeting B cell activity.
5.5. Cost of Voclosporin Treatment
The results from clinical trials related to VOC treatment in LN showed VOC’s clinical
effects on LN. Though the results are more in favor of VOC, the cost-effectiveness of VOC
will be a challenging task in the future as there is uncertainty around the cost-effectiveness
of VOC. According to one study, the cost-effectiveness of VOC is approximately USD
150,000 per quality-adjusted life years (QALYs) in the United States [86]. Notably, the
other emerging drugs, such as BEL, have approximately USD 95,000 per QALY,
suggesting that BEL was more cost effective [86]. Moreover, VOC costs GBP 1000 per 180-
pack of 7.9 mg soft capsules, while standard therapies such as MMF cost around GBP 6.23
per 50-pack of 500 mg tablets
(hps://www.nice.org.uk/guidance/ta882/resources/voclosporin-with-mycophenolate-
mofetil-for-treating-lupus-nephritis-pdf-82613730259141, Accessed on 11 January 2023).
Costs will certainly have an effect on the use and implementation of VOC into clinical
practice especially in limited resource seings.
6. Conclusions
As CsA and TAC remain associated with significant toxicities, the introduction of
VOC into clinical care is an important advancement of treatment options for LN and
possibly other autoimmune and proteinuric kidney diseases. VOC has a different
chemistry, pharmacology, and safety profile compared with CsA and TAC, namely, VOC
seems to lack nephrotoxicity. These aspects are an important asset when considering CNI
for chronic treatment of LN [3]. However, the problem of interference with other drug
classes that can cause additional toxicities in the context of certain co-medications
remains. The available evidence supports rapid and robust proteinuria control, which is
different from other immunosuppressants in use and in development for LN. Whether
rapid proteinuria control prevents irreversible injury beer than standard of care is not
yet known but is possible. This potential advantage would imply immediate and early use
of VOC in LN but may not necessarily argue for continued VOC therapy. Data on the
potential of VOC to control SLE and non-renal SLE manifestations are scarce, while these
Cells 2023, 12, 2440 13 of 16
are robust for alternative drug options such as BEL. How VOC will find its place in the
changing treatment landscape of LN is not yet clear.
Author Contributions: All authors wrote significant parts of the manuscript and have read and
agreed to the published version of the manuscript. All authors have read and agreed to the
published version of the manuscript.
Funding: H.-J.A. received funding from the Deutsche Forschungsgemeinschaft (AN372/30-1).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: H.-J.A. received consultancy fees and speaker honoraries from Otsuka and
GSK. The other authors have nothing to declare.
References
1. Engwenyu, L.R.; Anderson, A.S. A Comprehensive Review of Calcineurin Inhibitors Used for Immunosuppression in Cardiac
Transplantation. Handb. Exp. Pharmacol. 2022, 272, 27–38. hps://doi.org/10.1007/164_2021_549.
2. Safarini, O.A.; Keshavamurthy, C.; Patel, P. Calcineurin Inhibitors. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA,
2022.
3. Peleg, Y.; Bomback, A.S.; Radhakrishnan, J. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clin. J.
Am. Soc. Nephrol. 2020, 15, 1066–1072. hps://doi.org/10.2215/cjn.13761119.
4. Malakasioti, G.; Iancu, D.; Tullus, K. Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: A
systematic review. Pediatr. Nephrol. 2021, 36, 1353–1364. hps://doi.org/10.1007/s00467-020-04695-0.
5. Naesens, M.; Kuypers, D.R.; Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 2009, 4, 481–508.
hps://doi.org/10.2215/cjn.04800908.
6. Wu, Q.; Kuca, K. Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity. Curr. Drug Metab. 2019, 20, 84–
90. hps://doi.org/10.2174/1389200219666181031113505.
7. Ong, S.C.; Gaston, R.S. Thirty Years of Tacrolimus in Clinical Practice. Transplantation 2021, 105, 484–495.
hps://doi.org/10.1097/tp.0000000000003350.
8. Brunet, M.; van Gelder, T.; Åsberg, A.; Haufroid, V.; Hesselink, D.A.; Langman, L.; Lemaitre, F.; Marquet, P.; Seger, C.; Shipkova,
M.; et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther. Drug Monit. 2019,
41, 261–307. hps://doi.org/10.1097/ftd.0000000000000640.
9. van Gelder, T.; Lerma, E. Voclosporin: A novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev. Clin.
Pharmacol. 2022, 15, 515–529. hps://doi.org/10.1080/17512433.2022.2092470.
10. Heo, Y.A. Voclosporin: First Approval. Drugs 2021, 81, 605–610. hps://doi.org/10.1007/s40265-021-01488-z.
11. Li, W.; Shrivastava, M.; Lu, H.; Jiang, Y. Calcium-calcineurin signaling pathway in Candida albicans: A potential drug target.
Microbiol. Res. 2021, 249, 126786. hps://doi.org/10.1016/j.micres.2021.126786.
12. Creamer, T.P. Calcineurin. Cell Commun. Signal. 2020, 18, 137. hps://doi.org/10.1186/s12964-020-00636-4.
13. Ronan, P.J.; Flynn, S.A.; Beresford, T.P. Calcineurin signaling as a target for the treatment of alcohol abuse and
neuroinflammatory disorders. Prog. Mol. Biol. Transl. Sci. 2019, 167, 125–142. hps://doi.org/10.1016/bs.pmbts.2019.06.008.
14. Ponticelli, C.; Reggiani, F.; Moroni, G. Old and New Calcineurin Inhibitors in Lupus Nephritis. J. Clin. Med. 2021, 10, 4832.
15. Reiser, J.; Sever, S. Podocyte biology and pathogenesis of kidney disease. Annu. Rev. Med. 2013, 64, 357–366.
hps://doi.org/10.1146/annurev-med-050311-163340.
16. Garg, P. A Review of Podocyte Biology. Am. J. Nephrol. 2018, 47 (Suppl. S1), 3–13. hps://doi.org/10.1159/000481633.
17. Kopp, J.B.; Anders, H.J.; Susztak, K.; Podestà, M.A.; Remuzzi, G.; Hildebrandt, F.; Romagnani, P. Podocytopathies. Nat. Rev.
Dis. Prim. 2020, 6, 68. hps://doi.org/10.1038/s41572-020-0196-7.
18. Wakamatsu, A.; Fukusumi, Y.; Hasegawa, E.; Tomita, M.; Watanabe, T.; Narita, I.; Kawachi, H. Role of calcineurin (CN) in kidney
glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm. Physiol.
Rep. 2016, 4, 12679. hps://doi.org/10.14814/phy2.12679.
19. Shen, X.; Jiang, H.; Ying, M.; Xie, Z.; Li, X.; Wang, H.; Zhao, J.; Lin, C.; Wang, Y.; Feng, S.; et al. Calcineurin inhibitors cyclosporin
A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci. Rep. 2016, 6,
32087. hps://doi.org/10.1038/srep32087.
20. Shen, X.; Zhang, Y.; Lin, C.; Weng, C.; Wang, Y.; Feng, S.; Wang, C.; Shao, X.; Lin, W.; Li, B.; et al. Calcineurin inhibitors ameliorate
PAN-induced podocyte injury through the NFAT-Angptl4 pathway. J. Pathol. 2020, 252, 227–238.
hps://doi.org/10.1002/path.5512.
21. Ahlbach, C.L.; Lexa, K.W.; Bockus, A.T.; Chen, V.; Crews, P.; Jacobson, M.P.; Lokey, R.S. Beyond cyclosporine A: Conformation-
dependent passive membrane permeabilities of cyclic peptide natural products. Future Med. Chem. 2015, 7, 2121–2130.
hps://doi.org/10.4155/fmc.15.78.
Cells 2023, 12, 2440 14 of 16
22. Kazmi, S.; Mujeeb, A.A.; Owais, M. Cyclic undecapeptide Cyclosporin A mediated inhibition of amyloid synthesis: Implications
in alleviation of amyloid induced neurotoxicity. Sci. Rep. 2018, 8, 17283. hps://doi.org/10.1038/s41598-018-35645-4.
23. Wenger, R.M. Synthesis of ciclosporin and analogues: Structural and conformational requirements for immunosuppressive
activity. Prog. Allergy 1986, 38, 46–64.
24. Corbe, K.M.; Ford, L.; Warren, D.B.; Pouton, C.W.; Chalmers, D.K. Cyclosporin Structure and Permeability: From A to Z and
Beyond. J. Med. Chem. 2021, 64, 13131–13151. hps://doi.org/10.1021/acs.jmedchem.1c00580.
25. Wang, C.K.; Swedberg, J.E.; Harvey, P.J.; Kaas, Q.; Craik, D.J. Conformational Flexibility Is a Determinant of Permeability for
Cyclosporin. J. Phys. Chem. B 2018, 122, 2261–2276. hps://doi.org/10.1021/acs.jpcb.7b12419.
26. Kailasam, V.; Cheruvu, S.S.; Malani, M.; Kameswari, S.M.S.; Kesharwani, P.; Nirmal, J. Recent advances in novel formulation
approaches for tacrolimus delivery in treatment of various ocular diseases. J. Drug Deliv. Sci. Technol. 2022, 78, 103945.
hps://doi.org/10.1016/j.jddst.2022.103945.
27. Solionov, D.S.; Poshekhontseva, V.Y.; Fokina, V.V.; Shutov, A.A.; Nokilaeva, V.M.; Vasiarov, G.G.; Titova, E.V.; Karasev, V.S.;
Staroverov, S.M.; Donova, M.V. Biosynthesis of Tacrolimus by the Streptomyces tsukubensis VKM Ac-2618D Strain in the
Presence of Polymeric Sorbents and Development of a Method for Its Isolation and Purification. Appl. Biochem. Microbiol. 2020,
56, 699–707.
28. Ferraboschi, P.; Colombo, D.; De Mieri, M.; Grisenti, P. Evaluation, synthesis and characterization of tacrolimus impurities. J.
Antibiot. 2012, 65, 349–354. hps://doi.org/10.1038/ja.2012.28.
29. Skye, D.M.; Frydenvang, K.; Hansen, L.; Nielsen, P.G.; Jaroszewski, J.W. Synthesis and characterization of an epimer of
tacrolimus, an immunosuppressive drug. J. Nat. Prod. 2010, 73, 776–779. hps://doi.org/10.1021/np9007975.
30. Kuglstaer, A.; Mueller, F.; Kusznir, E.; Gsell, B.; Stihle, M.; Thoma, R.; Benz, J.; Aspeslet, L.; Freitag, D.; Hennig, M. Structural
basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr. D Biol.
Crystallogr. 2011, 67, 119–123. hps://doi.org/10.1107/s0907444910051905.
31. Roesel, M.; Tappeiner, C.; Heiligenhaus, A.; Heinz, C. Oral voclosporin: Novel calcineurin inhibitor for treatment of
noninfectious uveitis. Clin. Ophthalmol. 2011, 5, 1309–1313. hps://doi.org/10.2147/opth.s11125.
32. Dumont, F.J. ISAtx-247 (Isotechnika/Roche). Curr. Opin. Investig. Drugs 2004, 5, 542–550.
33. Wang, C.P.; Burckart, G.J.; Venkataramanan, R.; Ptachcinski, R.J.; Cuellar, R.E.; Makowka, L.; Van Thiel, D.H.; Starzl, T.E.
Cyclosporine Metabolite Profiles in the Blood of Liver Transplant Patients. Transplant. Proc. 1988, 20, 173–175.
34. Kempkes-Koch, M.; Fobker, M.; Erren, M.; August, C.; Gerhardt, U.; Suwelack, B.; Hohage, H. Cyclosporine A metabolite AM19
as a potential biomarker in urine for CSA nephropathy. Transplant. Proc. 2001, 33, 2167–2169. hps://doi.org/10.1016/s0041-
1345(01)01929-7.
35. Ling, S.Y.; Huizinga, R.B.; Mayo, P.R.; Freitag, D.G.; Aspeslet, L.J.; Foster, R.T. Pharmacokinetics of voclosporin in renal
impairment and hepatic impairment. J. Clin. Pharmacol. 2013, 53, 1303–1312. hps://doi.org/10.1002/jcph.166.
36. Patocka, J.; Nepovimova, E.; Kuca, K.; Wu, W. Cyclosporine A: Chemistry and Toxicity—A Review. Curr. Med. Chem. 2021, 28,
3925–3934. hps://doi.org/10.2174/0929867327666201006153202.
37. Morris, R.G. Cyclosporin therapeutic drug monitoring—An established service revisited. Clin. Biochem. Rev. 2003, 24, 33–46.
38. Han, K.; Pillai, V.C.; Venkataramanan, R. Population pharmacokinetics of cyclosporine in transplant recipients. AAPS J. 2013,
15, 901–912. hps://doi.org/10.1208/s12248-013-9500-8.
39. Yang, Y.; Li, P.; Zhang, Z.; Wang, Z.; Liu, L.; Liu, X. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically
Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes. Int. J. Mol. Sci. 2020, 21, 7023.
40. Wu, Q.; Wang, X.; Nepovimova, E.; Wang, Y.; Yang, H.; Kuča, K. Mechanism of cyclosporine A nephrotoxicity: Oxidative stress,
autophagy, and signalings. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2018, 118, 889–907.
41. Flores, C.; Fouquet, G.; Moura, I.C.; Maciel, T.T.; Hermine, O. Lessons to Learn From Low-Dose Cyclosporin-A: A New
Approach for Unexpected Clinical Applications. Front. Immunol. 2019, 10, 588. hps://doi.org/10.3389/fimmu.2019.00588.
42. Webb, N.J.A.; Baumann, U.; Camino, M.; Frauca, E.; Undre, N. Pharmacokinetics of tacrolimus granules in pediatric de novo
liver, kidney, and heart transplantation: The OPTION study. Pediatr. Transplant. 2019, 23, e13328.
hps://doi.org/10.1111/petr.13328.
43. Cury Martins, J.; Martins, C.; Aoki, V.; Gois, A.F.; Ishii, H.A.; da Silva, E.M. Topical tacrolimus for atopic dermatitis. Cochrane
Database Syst. Rev. 2015, 2015, Cd009864. hps://doi.org/10.1002/14651858.CD009864.pub2.
44. Schue-Nutgen, K.; Tholking, G.; Suwelack, B.; Reuter, S. Tacrolimus—Pharmacokinetic Considerations for Clinicians. Curr.
Drug Metab. 2018, 19, 342–350. hps://doi.org/10.2174/1389200219666180101104159.
45. Yu, M.; Liu, M.; Zhang, W.; Ming, Y. Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney
Transplantation. Curr. Drug Metab. 2018, 19, 513–522. hps://doi.org/10.2174/1389200219666180129151948.
46. Francke, M.I.; Hesselink, D.A.; Li, Y.; Koch, B.C.P.; de Wit, L.E.A.; van Schaik, R.H.N.; Yang, L.; Baan, C.C.; van Gelder, T.; de
Winter, B.C.M. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients.
Br. J. Clin. Pharmacol. 2021, 87, 1918–1929. hps://doi.org/10.1111/bcp.14585.
47. van Zyl, J.S.; Sam, T. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart
transplantation: Results of a single-center non-inferiority matched control trial. Clin. Transplant. 2021, 35, e14487.
hps://doi.org/10.1111/ctr.14487.
Cells 2023, 12, 2440 15 of 16
48. Kim, J.H.; Han, N.; Kim, M.G.; Yun, H.-Y.; Lee, S.; Bae, E.; Kim, Y.S.; Kim, I.-W.; Oh, J.M. Increased Exposure of Tacrolimus by
Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. Sci. Rep. 2018, 8, 1687.
hps://doi.org/10.1038/s41598-018-20071-3.
49. Mendez, R.; Gonwa, T.; Yang, H.C.; Weinstein, S.; Jensik, S.; Steinberg, S. A prospective, randomized trial of tacrolimus in
combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005, 80, 303–
309. hps://doi.org/10.1097/01.tp.0000167757.63922.42.
50. Zhang, X.; Lin, G.; Tan, L.; Li, J. Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic
considerations. Biomed. Pharmacother. 2018, 102, 107–114. hps://doi.org/10.1016/j.biopha.2018.03.054.
51. van Gelder, T. Drug interactions with tacrolimus. Drug Saf. 2002, 25, 707–712. hps://doi.org/10.2165/00002018-200225100-00003.
52. Shrestha, B.M. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences. Exp. Clin. Transplant. 2017,
15, 1–9. hps://doi.org/10.6002/ect.2016.0157.
53. Rovin, B.H.; Teng, Y.K.O.; Ginzler, E.M.; Arriens, C.; Caster, D.J.; Romero-Diaz, J.; Gibson, K.; Kaplan, J.; Lisk, L.; Navarra, S.; et
al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet 2021, 397, 2070–2080. hps://doi.org/10.1016/s0140-6736(21)00578-x.
54. Sin, F.E.; Isenberg, D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opin. Pharmacother. 2018, 19,
1613–1621. hps://doi.org/10.1080/14656566.2018.1516751.
55. van Gelder, T.; Huizinga, R.B.; Lisk, L.; Solomons, N. Voclosporin: A novel calcineurin inhibitor with no impact on
mycophenolic acid levels in patients with SLE. Nephrol. Dial. Transplant. 2022, 37, 917–922. hps://doi.org/10.1093/ndt/gfab022.
56. Bissonnee, R.; Papp, K.; Poulin, Y.; Lauzon, G.; Aspeslet, L.; Huizinga, R.; Mayo, P.; Foster, R.T.; Yatscoff, R.W.; Maksymowych,
W.P. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque
psoriasis. J. Am. Acad. Dermatol. 2006, 54, 472–478. hps://doi.org/10.1016/j.jaad.2005.10.061.
57. Busque, S.; Cantarovich, M.; Mulgaonkar, S.; Gaston, R.; Gaber, A.O.; Mayo, P.R.; Ling, S.; Huizinga, R.B.; Meier-Kriesche, H.U.
The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney
transplantation. Am. J. Transplant. 2011, 11, 2675–2684. hps://doi.org/10.1111/j.1600-6143.2011.03763.x.
58. Rovin, B.H.; Adler, S.G.; Barra, J.; Bridoux, F.; Burdge, K.A.; Chan, T.M.; Cook, H.T.; Fervenza, F.C.; Gibson, K.L.; Glassock,
R.J.; et al. KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. Suppl. 2021, 100, S1–S276.
59. Anders, H.J.; Kitching, A.R.; Leung, N.; Romagnani, P. Glomerulonephritis: Immunopathogenesis and immunotherapy. Nat.
Rev. Immunol. 2023, 23, 453–471. hps://doi.org/10.1038/s41577-022-00816-y.
60. Ronco, P.; Beck, L.; Debiec, H.; Fervenza, F.C.; Hou, F.F.; Jha, V.; Sethi, S.; Tong, A.; Vivarelli, M.; Weels, J. Membranous
nephropathy. Nat. Rev. Dis. Prim. 2021, 7, 69. hps://doi.org/10.1038/s41572-021-00303-z.
61. Fervenza, F.C.; Appel, G.B.; Barbour, S.J.; Rovin, B.H.; Lafayee, R.A.; Aslam, N.; Jefferson, J.A.; Gipson, P.E.; Rizk, D.V.; Sedor,
J.R.; et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N. Engl. J. Med. 2019, 381, 36–46.
hps://doi.org/10.1056/NEJMoa1814427.
62. Fernández-Juárez, G.; Rojas-Rivera, J.; Logt, A.V.; Justino, J.; Sevillano, A.; Caravaca-Fontán, F.; Ávila, A.; Rabasco, C.; Cabello,
V.; Varela, A.; et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is
superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021, 99, 986–
998. hps://doi.org/10.1016/j.kint.2020.10.014.
63. Mok, C.C.; Ho, L.Y.; Ying, S.K.Y.; Leung, M.C.; To, C.H.; Ng, W.L. Long-term outcome of a randomised controlled trial
comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann. Rheum. Dis. 2020, 79,
1070–1076. hps://doi.org/10.1136/annrheumdis-2020-217178.
64. Mok, C.C.; Ying, K.Y.; Yim, C.W.; Siu, Y.P.; Tong, K.H.; To, C.H.; Ng, W.L. Tacrolimus versus mycophenolate mofetil for
induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 2016, 75, 30–36.
hps://doi.org/10.1136/annrheumdis-2014-206456.
65. Alam, J.; de Souza, R.G.; Yu, Z.; Stern, M.E.; de Paiva, C.S.; Pflugfelder, S.C. Calcineurin Inhibitor Voclosporin Preserves Corneal
Barrier and Conjunctival Goblet Cells in Experimental Dry Eye. J. Ocul. Pharmacol. Ther. 2020, 36, 679–685.
hps://doi.org/10.1089/jop.2020.0005.
66. Cunningham, M.A.; Austin, B.A.; Li, Z.; Liu, B.; Yeh, S.; Chan, C.C.; Anglade, E.; Velagaleti, P.; Nussenbla, R.B. LX211
(voclosporin) suppresses experimental uveitis and inhibits human T cells. Investig. Ophthalmol. Vis. Sci. 2009, 50, 249–255.
hps://doi.org/10.1167/iovs.08-1891.
67. Liao, R.; Liu, Q.; Zheng, Z.; Fan, J.; Peng, W.; Kong, Q.; He, H.; Yang, S.; Chen, W.; Tang, X.; et al. Tacrolimus Protects Podocytes
from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis. PLoS ONE 2015, 10,
e0132724. hps://doi.org/10.1371/journal.pone.0132724.
68. Yamamoto, K.; Mori, A.; Nakahama, T.; Ito, M.; Okudaira, H.; Miyamoto, T. Experimental treatment of autoimmune MRL-lpr/lpr
mice with immunosuppressive compound FK506. Immunology 1990, 69, 222–227.
69. Fanouriakis, A.; Kostopoulou, M.; Cheema, K.; Anders, H.J.; Aringer, M.; Bajema, I.; Boletis, J.; Frangou, E.; Houssiau, F.A.;
Hollis, J.; et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European
Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann.
Rheum. Dis. 2020, 79, 713–723. hps://doi.org/10.1136/annrheumdis-2020-216924.
70. Anders, H.J.; Saxena, R.; Zhao, M.H.; Parodis, I.; Salmon, J.E.; Mohan, C. Lupus nephritis. Nat. Rev. Dis. Prim. 2020, 6, 7.
hps://doi.org/10.1038/s41572-019-0141-9.
Cells 2023, 12, 2440 16 of 16
71. Rovin, B.H.; Solomons, N.; Pendergraft, W.F., 3rd; Dooley, M.A.; Tumlin, J.; Romero-Diaz, J.; Lysenko, L.; Navarra, S.V.;
Huizinga, R.B. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin
with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019, 95, 219–231.
hps://doi.org/10.1016/j.kint.2018.08.025.
72. Anders, H.J.; Federico, R.; Birardi, V.; Leher, H. Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus
Nephritis Defined by EULAR/ERA Recommendations. Arthritis Rheum. 2022, 74, 708–710.
73. Anders, H.J.; Loutan, J.; Bruchfeld, A.; Juarez, G.M.F.; Floege, J.; Goumenos, D.; Turkmen, K.; van Kooten, C.; Frangou, E.;
Stevens, K.; et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrol. Dial.
Transplant. 2021, 38, 551–561. hps://doi.org/10.1093/ndt/gfab351.
74. Saxena, A.; Teng, Y.K.O.; Collins, C.; England, N.; Leher, H. Voclosporin for lupus nephritis: Results of the two year AURORA
2 continuation study. Ann. Rheum. Dis. 2022, 81, POSO186.
75. Steiger, S.; Ehreiser, L.; Anders, J.; Anders, H.J. Biological drugs for systemic lupus erythematosus or active lupus nephritis and
rates of infectious complications. Evidence from large clinical trials. Front. Immunol. 2022, 13, 999704.
hps://doi.org/10.3389/fimmu.2022.999704.
76. Parikh, S.V.; Arriens, C.; Yap, E.; Piper, K.; Huizinga, R.; Leher, H. Follow-up Kidney Biopsies from the AURORA 2 Clinical
Trial Evaluating Voclosporin for the Treatment of Lupus Nephritis. Clin. Congr. Rheumatol. 2023.
77. Furie, R.; Rovin, B.H.; Houssiau, F.; Malvar, A.; Teng, Y.K.O.; Contreras, G.; Amoura, Z.; Yu, X.; Mok, C.C.; Santiago, M.B.; et al.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N. Engl. J. Med. 2020, 383, 1117–1128.
hps://doi.org/10.1056/NEJMoa2001180.
78. Wallace, D.J.; Atsumi, T.; Daniels, M.; Hammer, A.; Meizlik, P.; Quasny, H.; Schwarting, A.; Zhang, F.; Roth, D.A. Safety of
belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial
data. Lupus 2022, 31, 1649–1659. hps://doi.org/10.1177/09612033221131183.
79. Malvar, A.; Pirruccio, P.; Alberton, V.; Lococo, B.; Recalde, C.; Fazini, B.; Nagaraja, H.; Indrakanti, D.; Rovin, B.H. Histologic
versus clinical remission in proliferative lupus nephritis. Nephrol. Dial. Transplant. 2017, 32, 1338–1344.
hps://doi.org/10.1093/ndt/gfv296.
80. Mejia-Vilet, J.M.; Malvar, A.; Arazi, A.; Rovin, B.H. The lupus nephritis management renaissance. Kidney Int. 2022, 101, 242–255.
hps://doi.org/10.1016/j.kint.2021.09.012.
81. Kirou, K.A.; Dall Era, M.; Aranow, C.; Anders, H.J. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit
assessment. Front. Immunol. 2022, 13, 980079. hps://doi.org/10.3389/fimmu.2022.980079.
82. Rovin, B.H.; Furie, R.; Teng, Y.K.O.; Contreras, G.; Malvar, A.; Yu, X.; Ji, B.; Green, Y.; Gonzalez-Rivera, T.; Bass, D.; et al. A
secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney
outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022, 101, 403–413.
hps://doi.org/10.1016/j.kint.2021.08.027.
83. Anders, H.J.; Peired, A.J.; Romagnani, P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney
disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions. Nephrol. Dial. Transplant. 2022, 37,
1609–1615. hps://doi.org/10.1093/ndt/gfaa329.
84. Heerspink, H.J.L.; Stefánsson, B.V.; Correa-Roer, R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.E.; McMurray, J.J.V.;
Lindberg, M.; Rossing, P.; et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020, 383, 1436–1446.
hps://doi.org/10.1056/NEJMoa2024816.
85. Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; Ng, S.Y.A.;
et al. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2023, 388, 117–127.
hps://doi.org/10.1056/NEJMoa2204233.
86. Mandrik, O.; Fotheringham, J.; Ren, S.; Tice, J.A.; Chapman, R.H.; Stevenson, M.D.; Pearson, S.D.; Herron-Smith, S.; Agboola,
F.; Thokala, P. The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.
Clin. J. Am. Soc. Nephrol. 2022, 17, 385–394.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury
to people or property resulting from any ideas, methods, instructions or products referred to in the content.
... Laboratory examination revealed leukopenia: 2300 mm 3 (n = 4000-1100), anaemia: haemoglobin 8.3 g/l (n: [12][13][14], and thrombocytopenia:132 000) (n = 150 000-400 000),iron value 48 mcg/dl (n = 60-170), total iron binding capacity 298 mcg/dl (n = 240-450), serum ferritin 87 ng/ml (n = 12-150), direct coombs was negative, reticulocyte 1% (n = 0.5-2.5%),vitamin B6 4.2 ug/l (n = 3.4-65.2), ...
... Calcineurin inhibitors such as voclosporin, cyclosporine, and tacrolimus act directly against T lymphocytes, aiming to decrease their activation and the release of cytokines resulting from it. These drugs are used as a second-line treatment in combination with mycophenolate mofetil [13] . First-line treatment of pancytopenia is glucocorticoid. ...
... First-line treatment of pancytopenia is glucocorticoid. In refractory cases, rituximab and immunosuppressants can be used [11][12][13] . ...
Article
Full-text available
Introduction Systemic Lupus Erythematosus is a systemic immune disease that classically occurs in young to middle-aged women and may present with cutaneous, renal, hematologic, neurological, and/or other symptoms at the time of diagnosis. Late-onset Systemic Lupus Erythematosus or Systemic Lupus Erythematosus in the elderly is a subtype that differs from classic Systemic Lupus Erythematosus in terms of age group, clinical symptoms, organ involvement and severity. Case presentation A 63 years old female noted to have pancytopenia. The patient was diagnosed with lupus upon obtaining clinical presentations and serological marker, along with high titers of the antinuclear antibody and/or anti-double-stranded DNA antibody. The patient was managed with glucocorticoids and mycophenolate mofetil therapy, which led to a rapid response. Discussion Late-onset SLE accounts for 2–12% of SLE patients with a minimum age of onset of 50 years and older, leading to significant delays in diagnosis. Late-onset SLE differs from early-onset SLE in terms of gender and ethnicity prevalence, clinical symptoms and signs, development of organ damage, disease activity and severity, and prognosis .Some studies have also shown that late-stage SLE patients have higher rates of RF and anti-Ro/anti-La antibody positivity, lower complement titer, and higher incidence of elevated creatinine and decreased creatinine clearance .First-line treatment of pancytopenia is glucocorticoid. In refractory cases, rituximab and immunosuppressants can be used. Conclusion It is important to assess any unusual presentation of Systemic Lupus Erythematosus when clinical suspicion remains high and conducting further laboratory and imaging investigation.
... Both the KDIGO 2024 and the European Alliance of Associations for Rheumatology 2023 guidelines endorse the use of calcineurin inhibitors for the treatment of lupus nephritis without specifying the subtype 11,95 . Calcineurin inhibitors easily demonstrate superiority in lupus nephritis trials for their potent antiproteinuric effects 96 . However, the calcineurin inhibitor cyclosporin A is a known nephrotoxic drug promoting kidney fibrosis, and the use of tacrolimus has been associated with a faster decline of eGFR and drug-induced diabetes 34,97 . ...
Article
Lupus nephritis is a common complication of systemic lupus erythematosus (SLE) and a determinant of overall morbidity and mortality, as lupus nephritis-related chronic kidney disease (CKD) drives cardiovascular disease and secondary immunodeficiency. Two lines of action are required to prevent the progression of lupus nephritis-related CKD: suppression of autoimmune SLE activity, which is a risk factor for immunopathology-related irreversible kidney injury, and management of non-immune risk factors that contribute to CKD progression. As each episode or relapse of active lupus nephritis implicates CKD progression, preventing flares of lupus nephritis is a key treatment target. Non-immune risk factors of CKD mostly include causes of nephron hyperfiltration, such as obesity, hypertension, sodium- or protein-rich diets and type 2 diabetes mellitus, as well as pregnancy. Nephrotoxic agents and smoking also drive kidney cell loss. Intrinsic risk factors for CKD progression include poor nephron endowment because of prematurity at birth, nephropathic genetic variants, ageing, male sex and previous or concomitant kidney diseases. Care for lupus nephritis involves the control of all modifiable risk factors of CKD progression. In addition, remnant nephron overload can be reduced using early dual therapy with inhibitors of the renin-angiotensin system and sodium-glucose transporter-2, whereas further renoprotective drug interventions are underway. As patients with lupus nephritis are at risk of CKD progression, they would all benefit from interdisciplinary care to minimize the risk of kidney failure, cardiovascular disease and infections.
... Although the favorable side effect profile of voclosporin, hypertension and drug-drug interactions still occur (33). High cost of voclosporin is also a consideration, especially in limited resource settings (34). In United States voclosporin is Food and Drug Administration approved for the treatment of LN on top of MMF and glucocorticoids. ...
Article
Full-text available
Systemic lupus erythematosus (SLE) is a complex autoimmune disease known for its high heterogeneity among individuals, which affects various organs including the kidneys. Lupus nephritis (LN) is a frequent and life-threatening manifestation of the disease, with up to 50% of patients developing kidney involvement. Classification of renal involvement in lupus is based on specific histopathological findings, guiding therapeutical decisions. Immunosuppressive therapy, particularly glucocorticoids combined with cyclophosphamide or mycophenolate mofetil, has been the mainstay of treatment for many years, while rates of complete remission have not changed dramatically. Despite advancements in therapy, in an important proportion of patients LN leads to end-stage kidney disease (ESKD). Emerging therapies including belimumab, voclosporin, and obinutuzumab offer promising results in improving renal outcomes, especially in refractory or relapsing disease. Maintenance therapy is crucial to prevent disease flares and preserve renal function. Supportive measures including lifestyle modifications and non-immunosuppressive pharmacological interventions are nowadays also essential in managing LN. This review emphasizes recent advances of therapy and challenges regarding treatment optimization with strategies to improve long-term outcomes.
... In the pivotal tacrolimus trial, an astonishing number of 213 participants (57.9%) did not complete the 24 weeks of the trial [7]. Importantly, the side effect spectrum of voclosporin and other calcineurin inhibitors, such as tacrolimus, is different, with voclosporin having lower frequencies of nephrotoxicity, neurotoxicity, dyslipidemia and de novo diabetes mellitus [8]. Most of these estimates stem from kidney transplant recipients. ...
Article
Full-text available
Lupus Nephritis (LN) still represents one of the most severe complications of Systemic Lupus Erythematosus (SLE) and a major risk factor for morbidity and mortality. However, over the last few years, several studies have paved the way for a deeper understanding of its pathogenetic mechanisms and more targeted treatments. This review aims to provide a comprehensive update on progress on several key aspects in this setting: pathogenetic mechanisms of LN, including new insight into the role of autoantibodies, complement, vitamin D deficiency, and interaction between infiltrating immune cells and kidney resident ones; the evolving role of renal biopsy and biomarkers, which may integrate information from renal histology; newly approved drugs such as voclosporin (VOC) and belimumab (BEL), allowing a more articulate strategy for induction therapy, and other promising phase III-immunosuppressive (IS) agents in the pipeline. Several adjunctive treatments aimed at reducing cardiovascular risk and progression of chronic renal damage, such as antiproteinuric agents, represent an important complement to IS therapy. Furthermore, non-pharmacological measures concerning general lifestyle and diet should also be adopted when managing LN. Integrating these therapeutic areas requires an effort towards a holistic and multidisciplinary approach. At the same time, the availability of an increasingly wider armamentarium may translate into improvements in patient’s renal outcomes over the next decades.
Conference Paper
Full-text available
Background Pooled data from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that adding voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil (MMF) and low-dose steroids resulted in significantly higher complete renal response rates at 24 weeks in AURA-LV (32.6% vs 19.3%; odds ratio [OR] 2.03; p=0.045) and 52 weeks in AURORA 1 (40.8% vs 22.5%; OR 2.65; p< 0.0001) in patients with lupus nephritis.The European League Against Rheumatism and European Renal Association (EULAR/ERA) published updated treatment recommendations for lupus nephritis with targeted reductions in proteinuria over the course of the first year of therapeutic intervention. Here we report on a post-hoc analysis of pooled data from the similarly-designed 48-week AURA-LV and 52-week AURORA 1 studies based on the recommended treatment targets. Methods AURA-LV and AURORA 1 enrolled patients with biopsy-proven active lupus nephritis (Class III, IV, or V ± III/IV) and proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V). Pooled data included 268 patients in the voclosporin arm and 266 patients in the control arm; all patients received MMF (target dose 2 g/day) and low-dose steroids (target dose 2.5 mg/day by week 16 according to protocol-defined steroid taper). We assessed the following EULAR/ERA treatment targets: ≥25% reduction in urine protein creatinine ratio (UPCR) at 3 months, ≥50% reduction in UPCR at 6 months, UPCR ≤0.7 mg/mg at 12 months, and steroid dose ≤7.5 mg/day at 12 months. Results After 3 months of treatment, 78.4% of patients in the voclosporin group and 62.4% of patients in the control group achieved ≥25% reduction in UPCR (odds ratio [OR] 2.25; 95% confidence interval [CI] 1.52, 3.33; p< 0.0001). The percentage of patients achieving a reduction of ≥50% in UPCR at 6 months was significantly greater in the voclosporin arm (66.0% vs 47.0%, respectively; OR 2.24; CI 1.57, 3.21; p< 0.0001). At 12 months, 52.6% and 33.1% of the voclosporin and control arms, respectively, had achieved a UPCR ≤0.7 mg/mg (OR 2.52; CI 1.75, 3.63; p< 0.0001). A total of 89.6% and 82.8% of patients in the voclosporin and control arms, respectively, had reached the recommended steroid dose of ≤7.5 mg/day at 12 months. The proportion of patients achieving a UPCR ≤0.7 mg/mg and having a steroid dose ≤7.5 mg/day at 12 months was 44.4% in the voclosporin arm and 27.1% in the control arm (OR 2.42; CI 1.66, 3.53; p< 0.0001). Conclusions The addition of voclosporin to a background regimen of MMF and low-dose steroids in patients with LN significantly increased the likelihood of achieving the 3-, 6-, and 12-month UPCR targets of therapy recommended by EULAR/ERA.
Article
Full-text available
Background This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. Methods We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligibility required an estimated glomerular filtration rate (eGFR) of ≥20 to <45 ml/minute/1.73m²; or ≥45 to <90 ml/minute/1.73m² with a urinary albumin-to-creatinine ratio (ACR) of ≥200 mg/g. The primary outcome was a composite of kidney disease progression (end-stage kidney disease, a sustained eGFR <10 ml/minute/1.73m², a sustained decline in eGFR of ≥40%, or a renal death) or death from cardiovascular causes. Results During a median of 2.0 years follow-up, a primary outcome event occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% CI 0.64 to 0.82; P<0.001), with consistent results in those with or without diabetes and across the range of eGFR studied. There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003), but no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%), or death from any cause (4.5% vs 5.1%). The rates of serious adverse events were broadly similar in the two groups. Conclusions Empagliflozin reduced the risk of the composite outcome of kidney disease progression or cardiovascular death in a wide range of patients at risk of CKD progression. (Funding:Boehringer Ingelheim, Eli Lilly and others; Clinicaltrials.gov:NCT03594110, EuDRACT: 2017-002971-24).
Article
Full-text available
Objectives Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that affects multiple organ systems. Belimumab, a targeted human monoclonal antibody, binds to and inhibits soluble B-lymphocyte stimulator. The safety and efficacy of belimumab has consistently been demonstrated in multiple clinical trials for the treatment of patients with active SLE. Integration of these data provides an additional opportunity to explore the safety of belimumab in a larger and more diverse population. This post hoc pooled analysis of clinical studies evaluated the safety profile of belimumab versus placebo in adults with SLE. Methods This was a pooled post hoc analysis of 52-week safety data from one Phase 2 and five Phase 3 belimumab trials in adult patients with SLE. Patients received ≥1 dose of placebo or belimumab (1, 4, or 10 mg/kg intravenous or 200 mg subcutaneous), plus standard therapy. Outcomes included the incidence of adverse events (AEs), serious AEs (SAEs), severe AEs, AEs of special interest (AESI), and mortality. Results Across 4170 patients (placebo: N = 1355; belimumab: N = 2815), baseline demographics, disease characteristics, and treatment exposure were similar for placebo and belimumab. Most patients (placebo: 76.6%; belimumab: 81.0%) completed the protocol Week 52 visit. Overall, incidence of AEs, SAEs, severe AEs, AESI, and mortality were similar between groups. In both groups, the most commonly reported SAEs by system organ class were infections and infestations (placebo: 5.9%; belimumab: 5.4%) and renal and urinary disorders (placebo: 2.2%; belimumab: 1.7%). Additionally, a greater proportion of patients experienced AESI with belimumab versus placebo for post-infusion/injection systemic reactions (placebo: 8.1%; belimumab: 10.2%). Mortality rates were similar between groups (placebo: 0.4%; belimumab: 0.6%). Conclusions These results are consistent with those of the individual studies, BASE, BLISS-LN, and long-term extension studies, making belimumab one of the most studied SLE treatments for safety. Collectively, this evidence continues to support a positive benefit–risk profile of belimumab in the treatment of adult patients with SLE.
Article
Full-text available
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that frequently affects the kidneys, known as lupus nephritis (LN). Such patients are treated with antimalarials, corticosteroids or immunosuppressive drugs, and more recently, target-specific biological drugs. Although efficacy of these therapies improved SLE-related outcomes, SLE remains associated with higher rates of infections. Here, we performed a comprehensive systemic review of infectious complications in clinical trials covering drug interventions for SLE or specifically for active LN. Our search in 15 online registries yielded a total of 1477 studies of which 14 matched our prespecified criteria. These covered the biological drugs anifrolumab, belimumab, and rituximab that were tested in patients with non-renal SLE and active LN.The available safety data from the SLE trials indicated that infectious complications such as herpes zoster, upper respiratory tract infection, nasopharyngitis, bronchitis, and urinary tract infection in patients receiving placebo were quite prevalent especially in the EXPLORER (rituximab) trial. Infections occurred mostly during the first year of LN therapy. Serious adverse events and infectious complications occurred more frequently in placebo-treated patients with active LN, especially in the BLISS-LN (belimumab) and LUNAR (rituximab) trials. Anifrolumab and rituximab increased the number of clinically relevant episodes of herpes zoster compared to belimumab in patients with active LN. Anifrolumab displayed a similar trend for influenza infections, which is consistent with the specific mechanisms-of-action of anifrolumab; highlighting drug-specific effects on infectious complications. In addition, standard-of-care therapy, e.g., MMF and immunosuppressants, as well as a longer SLE duration may also affect the incidence of serious adverse events and certain infectious complications in SLE patients with active LN.Infectious complications are common in SLE but even more common in patients with active LN, especially herpes zoster is strongly associated with active LN and anifrolumab therapy (OR 2.8, 95% CI 1.18 to 6.66, p = 0.018). Immunotherapy seems to impose unspecific and specific risks for infections. The latter may imply specific precautions such as preemptive vaccination and individual risk-benefit assessments.
Article
Full-text available
Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively unselective immunosuppressive properties. However, two target-specific biological drugs have been approved: belimumab (anti-B-cell-activating factor/BAFF) and anifrolumab (anti-interferon alpha receptor-1/IFNAR1). Here, we performed a comparative risk-benefit assessment for both drugs based on the role of BAFF and IFNAR1 in host defense and the pathogenesis of SLE and by considering the available data on safety and efficacy. Due to differences in target expression sites, anti-IFNAR1, but not anti-BAFF, might elicit organ-specific effects, consistent with clinical efficacy data. The IFNAR1 is specifically involved in innate and adaptive antiviral immunity in most cells of the body. Consistent with this observation, the available safety data obtained from patients negatively selected for LN and neuropsychiatric SLE, primary immunodeficiencies, splenectomy and chronic HIV, HBV, HCV infections suggest an increased risk for some viral infections such as varicella zoster and perhaps influenza. In contrast, BAFF is mainly involved in adaptive immune responses in lymphoid tissues, thus anti-BAFF therapy modulates SLE activity and prevents SLE flares without interfering with local innate host defense mechanisms and should only marginally affect immune memory to previous pathogen exposures consistent with the available safety data from SLE patients without chronic HIV, HBV or HCV infections. When using belimumab and anifrolumab, careful patient stratification and specific precautions may minimize risks and maximize beneficial treatment effects for patients with SLE.
Article
Full-text available
Introduction: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus. Standard-of-care immunosuppressive therapies achieve poor complete renal response (CRR) rates, with considerable toxicity. This article reviews voclosporin, a novel oral calcineurin inhibitor (CNI) approved for treatment of adults with active LN by the US Food and Drug Administration (the FDA) in January 2021. Areas covered: : This review summarizes the chemical properties, pharmacokinetics, and pharmacodynamics of voclosporin, and its efficacy and safety in LN, based on literature review covering PubMed searches, manufacturers' websites and documents produced by the FDA. Expert opinion: : Voclosporin is a CNI with a consistent pharmacokinetic-pharmacodynamic relationship resulting from enhanced calcineurin binding and reduced drug and metabolite load. This profile permits therapeutic efficacy in LN at a dose associated with relatively low calcineurin inhibition, and therefore a potentially improved safety profile. Pivotal trials demonstrated a significant benefit of adding voclosporin to standard therapy, with rapid reduction in proteinuria, and a clinically meaningful and significantly higher CRR rate at 1 year. At approved doses for LN, potential advantages of voclosporin versus historical experience with CNIs include lack of need for therapeutic drug monitoring, benign metabolic, lipid and electrolyte profile, and no impact on mycophenolate mofetil levels.
Article
‘Glomerulonephritis’ (GN) is a term used to describe a group of heterogeneous immune-mediated disorders characterized by inflammation of the filtration units of the kidney (the glomeruli). These disorders are currently classified largely on the basis of histopathological lesion patterns, but these patterns do not align well with their diverse pathological mechanisms and hence do not inform optimal therapy. Instead, we propose grouping GN disorders into five categories according to their immunopathogenesis: infection-related GN, autoimmune GN, alloimmune GN, autoinflammatory GN and monoclonal gammopathy-related GN. This categorization can inform the appropriate treatment; for example, infection control for infection-related GN, suppression of adaptive immunity for autoimmune GN and alloimmune GN, inhibition of single cytokines or complement factors for autoinflammatory GN arising from inborn errors in innate immunity, and plasma cell clone-directed or B cell clone-directed therapy for monoclonal gammopathies. Here we present the immunopathogenesis of GN and immunotherapies in use and in development and discuss how an immunopathogenesis-based GN classification can focus research, and improve patient management and teaching.
Article
Tacrolimus, in spite of its good safety profile with fewer adverse effects (when treated locally) is still being used as an off-label drug to treat ocular diseases - like corneal graft-versus-host disease, conjunctivitis, uveitis and dry eye. Poor aqueous solubility, stability and permeability are the major challenges to develop tacrolimus as an ocular therapy. Currently, several novel delivery systems such as nanomicelles, proniosomes, inclusion complexes, liposomes and nano emulsion are being developed to address these challenges. This review aims to provide a detailed discussion on the various delivery strategies for tacrolimus with their advantages as well as their limitations. We have also reviewed the mechanism of action of tacrolimus in treating various ocular diseases along with its development and rising importance in replacing steroidal therapy.
Article
Background The novel calcineurin inhibitor voclosporin was approved in 2021 for the treatment of adult patients with active lupus nephritis (LN) in combination with background immunotherapy. Voclosporin has a favorable metabolic profile and a consistent dose-concentration relationship, eliminating the need for therapeutic drug monitoring. The Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to significantly higher complete renal response rates in AURA-LV at 24 weeks (32.6% vs 19.3%; odds ratio [OR] 2.03; p=0.046) and in AURORA 1 at 52 weeks (40.8% vs 22.5%; OR 2.65; p<0.0001) of treatment in patients with LN. Objectives The European League Against Rheumatism and European Renal Association (EULAR/ERA) published updated treatment recommendations for LN with targeted reductions in proteinuria over the course of the first year of therapeutic intervention. ¹ Here we report on a post-hoc analysis of pooled data from the similarly designed 48-week AURA-LV and 52-week AURORA 1 studies based on these updated response criteria. Methods AURA-LV and AURORA 1 enrolled patients with biopsy-proven active lupus nephritis (Class III, IV, or V ± III/IV) and proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V). Pooled data included 268 patients in the voclosporin (23.7 mg BID) group and 266 patients in the control group, with all patients receiving MMF (target dose 1 g BID) and low-dose steroids (target dose 2.5 mg/day by week 16 according to protocol-defined steroid taper). We assessed the following EULAR/ERA treatment targets: ≥25% reduction in urine protein creatinine ratio (UPCR) by 3 months, ≥50% reduction in UPCR by 6 months, UPCR ≤0.7 mg/mg by 12 months, and steroid dose ≤7.5 mg/day by 3, 6, and 12 months. Results Within the first 3 months of treatment, 78.4% of patients in the voclosporin group and 62.4% of patients in the control group achieved ≥25% reduction in UPCR (odds ratio [OR] 2.25; 95% confidence interval [CI] 1.52, 3.33; p<0.0001). The percentage of patients achieving a reduction of ≥50% in UPCR by 6 months was also significantly greater in the voclosporin group compared to control (66.0% vs 47.0%, respectively; OR 2.24; CI 1.57, 3.21; p<0.0001). After 12 months of treatment, 52.6% and 33.1% of patients receiving voclosporin and control, respectively, had achieved a UPCR ≤0.7 mg/mg (OR 2.52; CI 1.75, 3.63; p<0.0001). Given the protocol-defined steroid taper, at both 3 and 6 months, a similar proportion (>90%) of patients in both groups had achieved the recommended steroid dose, with 89.6% and 82.8% in the voclosporin and control groups, respectively, on the recommended dose at 12 months. The proportion of patients meeting all three UPCR targets during the one-year study period and having a steroid dose ≤7.5 mg/day at 12 months was 37.3% in the voclosporin group and 23.3% in the control group (OR 2.11; CI 1.43, 3.10; p=0.0001). Conclusion The addition of voclosporin to a background regimen of MMF and low-dose steroids in patients with LN significantly increased the likelihood of achieving the 3-, 6-, and 12-month UPCR targets of therapy recommended by EULAR/ERA. References [1]Fanouriakis, A. et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713–723 (2020). Figure 1. Integrated AURA-LV and AURORA 1 Analysis on the Achievement of UPCR Treatment Targets and Use of Low-Dose Steroids per EULAR/ERA Lupus Nephritis Recommendations Disclosure of Interests Hans-Joachim Anders: None declared, Ray Federico Shareholder of: Aurinia Pharmaceuticals Inc., Employee of: Aurinia Pharmaceuticals Inc., Simrat Randhawa Shareholder of: Aurinia Pharmaceuticals Inc., Employee of: Aurinia Pharmaceuticals Inc., Henry Leher Shareholder of: Aurinia Pharmaceutical Inc., Employee of: Aurinia Pharmaceutical Inc.
Article
Background Voclosporin (VCS), a novel calcineurin inhibitor, was approved in the US in January 2021 for the treatment of adult patients with active lupus nephritis (LN) in combination with background immunosuppressive therapy. The Phase 3 AURORA 1 study showed that the addition of VCS to mycophenolate mofetil (MMF) and low-dose steroids in patients with LN significantly increased rates of complete renal response at 52 weeks. Objectives Here we report the results of the completed continuation study, AURORA 2, which assessed the long-term safety and tolerability of VCS compared to placebo in patients with LN receiving treatment for an additional 24 months following completion of the AURORA 1 study Methods Key inclusion criteria for the parent AURORA 1 study included a diagnosis of biopsy-proven active LN (Class III, IV, or V ± III/IV), proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V) and estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m ² . Patients who completed AURORA 1 and who elected and were eligible to enter AURORA 2 continued on the same blinded therapy as at the end of AURORA 1 (either VCS or placebo twice daily in combination with MMF and low-dose steroids). Safety and tolerability were monitored, and eGFR, serum creatinine (SCr), and urine protein creatinine ratio (UPCR) were also assessed. Results In total, 116 and 100 patients in the VCS and control arms enrolled in AURORA 2, with 92 (79.3%) and 73 (73.0%) patients in each respective arm receiving treatment to the end of AURORA 2. There were no unexpected safety signals in the VCS arm compared to control, with similar rates of serious adverse events reported in both arms (VCS [18.1%] vs. control [23.0%]; Table 1). Eight patients in each arm experienced serious adverse events of infection; serious coronavirus infections were observed in 2 patients in the voclosporin arm and 5 patients in the control arm. There were 4 and 2 adverse events by preferred term of renal impairment reported in the VCS and control arms, respectively, none of which were considered serious, and no reports of acute kidney injury by preferred term in either arm. There were no deaths in the VCS arm during AURORA 2; four deaths were reported in the control arm (pulmonary embolism [n=1], coronavirus infection [n=3]). Mean eGFR and SCr levels remained stable through the end of AURORA 2. The difference between the VCS and control arms in LS mean change from baseline in eGFR was 2.7 mL/min/1.73 m ² at 4 weeks following study drug discontinuation (Figure 1). The mean reductions in UPCR observed in patients treated with VCS in AURORA 1 were maintained in AURORA 2 with no increase in UPCR noted at the follow-up visit 4 weeks after study drug discontinuation. Table 1. Overall Summary of Adverse Events Control(n=100) Voclosporin(n=116) n (%) n (%) Any AE 80 (80.0) 100 (86.2) Renal Impairment 2 (2.0) 4 (3.4) Acute Kidney Injury 0 0 Treatment-related AE 21 (21.0) 28 (24.1) Serious AE 23 (23.0) 21 (18.1) Serious Treatment-related AE 2 (2.0) 1 (0.9) AE Leading to Study Drug Discontinuation 17 (17.0) 11 (9.5) Death 4 (4.0) 0 Treatment-related Death 0 0 Figure 1. LS Mean eGFR over Time Conclusion Voclosporin was well-tolerated over 3 years of treatment with no unexpected safety signals detected. Further, eGFR remained stable throughout the study period, and the significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. These data provide evidence of a long-term treatment benefit of VCS in patients with LN. Includes adverse events starting on or after the first dose of study drug in AURORA 2 up to 30 days after the last dose and all events of death reported during study follow-up. Adverse events were aggregated by System Organ Class and Preferred Term and coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0. AE, adverse event. Disclosure of Interests Amit Saxena Speakers bureau: Aurinia Pharmaceuticals Inc., Consultant of: Aurinia Pharmaceuticals Inc., Y.K. Onno Teng Consultant of: Aurinia Pharmaceuticals Inc., Chris Collins Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals, Nicole England Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals, Henry Leher Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals